相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs
A. Naing et al.
ANNALS OF ONCOLOGY (2012)
Cost Control in a Parallel Universe: Medicare Spending in the United States and Canada
David U. Himmelstein et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine
Sharyl J. Nass et al.
AMERICAN JOURNAL OF THERAPEUTICS (2011)
Projections of the Cost of Cancer Care in the United States: 2010-2020
Angela B. Mariotto et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Bending the Cost Curve in Cancer Care
Thomas J. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer's Next Frontier Addressing High and Increasing Costs
Elena B. Elkin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research
David J. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Medical Bankruptcy in the United States, 2007: Results of a National Study
David U. Himmelstein et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Cancer: The Road to Amiens
David J. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Ordinary Miracle of Cancer Clinical Trials
David P. Steensma
JOURNAL OF CLINICAL ONCOLOGY (2009)
Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program
David M. Dilts et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
Bruce E. Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Chris P. Lee et al.
VALUE IN HEALTH (2009)
Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group
David M. Dilts et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
DALYs and QALYs in developing countries
Victor Zarate
HEALTH AFFAIRS (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials
David M. Dilts et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
分享论文
